Transparency Market Research

Pouchitis Treatment Market Is Expected to Experience a Swift Development by 2025


Albany, NY -- (SBWIRE) -- 07/09/2018 -- Pouchitis is an inflammatory condition of the ileal pouch. It happens when the ileal pouch reservoir becomes inflamed or irritated. Pouchitis mainly occurs in a patient who has undergone ileal pouch-anal anastomosis (IPAA), a surgical procedure for removing the rectum and the large intestine. About half of the number of patients who undergo this surgery develops pouchitis at least once in their lifetime. Every year, up to 40% of patients who undergo IPAA surgery develops pouchitis. However, the exact cause of pouchitis has not yet been determined. Pouchitis has been observed occurring among patients suffering from ulcerative colitis or some other form of colitis, and also rarely among patients with genetic condition (familial adenomatous polyposis), in which many polyps are formed in the colon. Other factors responsible for the development of pouchitis include backwash ileitis, long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs), increased number of platelets, smoking, and health conditions such as diabetes or heart disease. Common symptoms of pouchitis include tenesmus, straining during defecation, blood in stool, seepage of waste matter while asleep, incontinence, tail bone pain, abdominal cramp, and increased frequency in night-time bowel movements.

Options presently available for the treatment of pouchitis include antibiotics, budesonide enemas, probiotics, glutamine suppositories, butyrate suppositories, bismuth enemas, allopurinol, and tinidazole. The global Pouchitis Treatment Market is expected to expand at a significant CAGR during the forecast period as there is not a single therapy has been approved in the US and Europe for the treatment of pouchitis. However, a few pipeline molecules are waiting for approval, such as alicaforsen, the molecule developed by Atlantic Healthcare plc. Rise in the prevalence of ulcerative colitis, increase in the number of ileal pouch-anal anastomosis procedure, long-term usage of non-steroidal anti-inflammatory drugs, and growth in the geriatric population are the key factors driving the global pouchitis treatment market. However, disappointing result of promising pipeline molecules and stringent government regulations are anticipated to hamper the growth of the global pouchitis treatment market during the forecast period.

Request to View Brochure of Report -

Geographically, the global pouchitis treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America, followed by Europe, is anticipated to be a dominant pouchitis treatment market for pouchitis treatment during the forecast period. High incidence of pouchitis, rise in the number of patients undergoing ileal pouch-anal anastomosis, increase in R&D expenditure, ongoing intensive research on bowel complications, and well-established healthcare infrastructure, among other factors contribute to the growth of the pouchitis treatment market in North America. The pouchitis treatment market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, the growth being primarily driven by India and China owing to the large patient base undergoing ileal pouch-anal anastomosis, increased incidence of ulcerative colitis, rise in awareness regarding the disease, increased government initiatives toward healthcare, and developing healthcare infrastructure in these countries. The pouchitis treatment market in Latin America and Middle East & Africa is anticipated to expand during the forecast period due to rise in prevalence of pouchitis and upsurge in investments by pouchitis treatment market players in these regions.

The leading players in the global pouchitis treatment market include Atlantic Healthcare, Pfizer, Allergan Plc, Abbott, Alfa sigma, Bayer, Takeda Pharmaceutical Company Limited, AstraZeneca, Tillotts Pharma AG, Novartis AG, Astellas Pharma Inc., Synergy Pharmaceuticals, Inc., Valeant Pharmaceuticals, Sucampo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sebela Pharmaceuticals, Sanofi, Ironwood Pharmaceuticals, Inc., Ardelyx, Inc., and Probi.

Enquiry for discount on this report -